OS rates for IMpower133 and IMbrella A extension study in SCLC

Biagio Ricciuti shared a paper by Martin Reck et al. on X, adding:

“Five-year survival in patients with extensive-stage SCLC treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella A extension study.

3y OS rate 16%, 4y OS 13%, 5y OS 12%.”

Source: Biagio Ricciuti/X

Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella a extension study.

Authors: Martin Reck, Rafal Dziadziuszko, Shunichi Sugawara, Steven Kao, Maximilian Hochmair, Florian Huemer, Gilberto de Castro, Libor Havel, Reyes Bernabé Caro, György Losonczy, Jong-Seok Lee, Dariusz M. Kowalski, Zoran Andric, Raffaele Califano, Andrea Veatch, Gregory Gerstner, Marta Batus, Stefanie Morris, Monika Kaul, Vaikunth Cuchelkar, Huafei Li, Bradford J. Danner, Barzin Y. Nabet, and Stephen V. Liu.

Biagio Ricciuti is a thoracic oncologist at the Dana-Farber Cancer Institute and an Assistant Professor of Medicine at Harvard Medical School.

His research interests are various aspects of lung cancer, including novel therapeutics, biomarker identification, and predictive modeling for patient outcomes. Besides being actively engaged in research, Dr. Ricciuti is involved in clinical trials and patient care.